Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis
Authors
G.S. Park
Jakub Trefler (ORCID: https://orcid.org/0009-0003-3912-3518)
Janusz Jaworski (ORCID: https://orcid.org/0000-0002-2664-1012)
Piotr Adrian Klimiuk (ORCID: https://orcid.org/0000-0003-3457-6203)
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis
G.S. Park, Jakub Trefler, Janusz Jaworski, Piotr Adrian Klimiuk et al.
Citations
4 citations
Journal
Clinical Drug Investigation
Topics
Biosimilars and Bioanalytical Methods
Field-Weighted Citation Impact (FWCI)
3.19
article
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis
G.S. Park, Jakub Trefler, Janusz Jaworski, Piotr Adrian Klimiuk, Katarzyna Kolossa, Rafał Wojciechowski, Sławomir Jeka, Paweł Hrycaj, YunAh Kim, Yeonsoon Jung, Sung Hyun Kim, Agnieszka Zielińska, Marek Krogulec, Go Eun Yang, Anna Dudek, Gerd R Burmester, Artur Racewicz, Magdalena Krajewska–Włodarczyk, Josef S Smolen, JeeHye Suh
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
Clinical Drug InvestigationVol. 45(8)
Institutions
Medical University of Białystok (PL), Meditest (PL), University of Management and Administration in Zamosc (PL), University of Bydgoszcz (PL), Centrum Medyczne iMed24 (PL), Ocná klinika (SK), College of Social and Media Culture (PL), Celltrion (South Korea) (KR), University of Warmia and Mazury in Olsztyn (PL), Medical University of Vienna (AT), Charité - Universitätsmedizin Berlin (DE)
Funders
Celltrion, Universität Wien, Medizinische Universität Wien